<DOC>
	<DOC>NCT02207816</DOC>
	<brief_summary>The purpose of this study is to conduct long-term surveillance for efficacy, safety and immunogenicity of the GSK Biologicals RTS,S/AS01E candidate Plasmodium falciparum malaria vaccine in infants and children in Africa following a primary vaccination series (NCT00866619). No new subjects will be enrolled in this extension study.</brief_summary>
	<brief_title>An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects' parent(s)/ Legally Acceptable Representative (LARs) who, in the opinion of the investigator, can and will comply with the requirements of the protocol. Subjects who were enrolled and who received at least one vaccine dose in the primary study MALARIA055 PRI NCT00866619 and who did not withdraw consent (except those who moved away from the area) during the primary study MALARIA055 PRI NCT00866619. Written informed consent obtained from the parent(s)/LAR(s) of the subject. Child in care. Use of any investigational or nonregistered product or planned use during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>42 Months</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Infants</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Children</keyword>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Safety</keyword>
	<keyword>Surveillance</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>RTS,S/AS01E</keyword>
	<keyword>Africa</keyword>
</DOC>